Mycobacterium tuberculosis resistance prediction and lineage classification from genome sequencing: comparison of automated analysis tools

Whole-genome sequencing (WGS) has the potential to accelerate drug-susceptibility testing (DST) to design appropriate regimens for drug-resistant tuberculosis (TB). Several recently developed automated software tools promise to standardize the analysis and interpretation of WGS data. We assessed five tools (CASTB, KvarQ, Mykrobe Predictor TB, PhyResSE, and TBProfiler) with regards to DST and phylogenetic lineage classification, which we compared with phenotypic DST, Sanger sequencing, and traditional typing results for a collection of 91 strains. The lineage classifications by the tools generally only differed in the resolution of the results. However, some strains could not be classified at all and one strain was misclassified. The sensitivities and specificities for isoniazid and rifampicin resistance of the tools were high, whereas the results for ethambutol, pyrazinamide, and streptomycin resistance were more variable. False-susceptible DST results were mainly due to missing mutations in the resistance catalogues that the respective tools employed for data interpretation. Notably, we also found cases of false-resistance because of the misclassification of polymorphisms as resistance mutations. In conclusion, the performance of current WGS analysis tools for DST is highly variable. Sustainable business models and a shared, high-quality catalogue of resistance mutations are needed to ensure the clinical utility of these tools. Supplementary information The online version of this article (doi:10.1038/srep46327) contains supplementary material, which is available to authorized users.

[1]  Hilla Peretz,et al.  Ju n 20 03 Schrödinger ’ s Cat : The rules of engagement , 2003 .

[2]  J. Heyckendorf,et al.  Getting personal perspectives on individualized treatment duration in multidrug-resistant and extensively drug-resistant tuberculosis. , 2014, American journal of respiratory and critical care medicine.

[3]  Marco Schito,et al.  Collaborative Effort for a Centralized Worldwide Tuberculosis Relational Sequencing Data Platform. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  C. Vilchèze,et al.  Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid , 2006, Nature Medicine.

[5]  Dennis Andersson,et al.  A retrospective cohort study , 2018 .

[6]  B. Metchock,et al.  Molecular and Growth-Based Drug Susceptibility Testing of Mycobacterium tuberculosis Complex for Ethambutol Resistance in the United States , 2016, Tuberculosis research and treatment.

[7]  C. Köser,et al.  Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  J. O’Grady,et al.  The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs , 2016, Genome Medicine.

[9]  J. Parkhill,et al.  Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDRsl Assays , 2017, Antimicrobial Agents and Chemotherapy.

[10]  Matthias Reumann,et al.  WGS Analysis and Interpretation in Clinical and Public Health Microbiology Laboratories: What Are the Requirements and How Do Existing Tools Compare? , 2014, Pathogens.

[11]  M. Pallen,et al.  Whole-Genome Sequencing for Rapid Susceptibility Testing of M. tuberculosis , 2013 .

[12]  G. Kahlmeter,et al.  Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis. , 2012, Bulletin of the World Health Organization.

[13]  J. Parkhill,et al.  dfrA thyA Double Deletion in para-Aminosalicylic Acid-Resistant Mycobacterium tuberculosis Beijing Strains , 2016, Antimicrobial Agents and Chemotherapy.

[14]  Stefan Niemann,et al.  Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. , 2014, The Journal of antimicrobial chemotherapy.

[15]  T. Clark,et al.  Removing the bottleneck in whole genome sequencing of Mycobacterium tuberculosis for rapid drug resistance analysis: a call to action. , 2017, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[16]  E. Böttger The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[17]  N Woodford,et al.  The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[18]  G. Dougan,et al.  Routine Use of Microbial Whole Genome Sequencing in Diagnostic and Public Health Microbiology , 2012, PLoS pathogens.

[19]  F. Dafae,et al.  Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting , 2012, BMC Microbiology.

[20]  S. Niemann,et al.  Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study , 2014, mBio.

[21]  S. Niemann,et al.  Drug-resistance mechanisms and tuberculosis drugs , 2015, The Lancet.

[22]  Francesc Coll,et al.  A robust SNP barcode for typing Mycobacterium tuberculosis complex strains , 2014, Nature Communications.

[23]  G. Smith,et al.  Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. , 2013, The New England journal of medicine.

[24]  S. Niemann,et al.  Importance of the Genetic Diversity within the Mycobacterium tuberculosis Complex for the Development of Novel Antibiotics and Diagnostic Tests of Drug Resistance , 2012, Antimicrobial Agents and Chemotherapy.

[25]  L. Rigouts,et al.  Rifampin Resistance Missed in Automated Liquid Culture System for Mycobacterium tuberculosis Isolates with Specific rpoB Mutations , 2013, Journal of Clinical Microbiology.

[26]  Francesc Coll,et al.  Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences , 2015, Genome Medicine.

[27]  Phelim Bradley,et al.  Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study , 2015, The Lancet. Infectious diseases.

[28]  S. Borrell,et al.  KvarQ: targeted and direct variant calling from fastq reads of bacterial genomes , 2014, BMC Genomics.

[29]  D. Hay,et al.  Call for action. , 1971, Nursing mirror and midwives journal.

[30]  Lukas Fenner,et al.  Two New Rapid SNP-Typing Methods for Classifying Mycobacterium tuberculosis Complex into the Main Phylogenetic Lineages , 2012, PloS one.

[31]  F. Drobniewski,et al.  True rifampicin resistance missed by the MGIT: prevalence of this pheno/genotype in the UK and Ireland after 18 month surveillance. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  Stefan Niemann,et al.  Genotyping of Genetically Monomorphic Bacteria: DNA Sequencing in Mycobacterium tuberculosis Highlights the Limitations of Current Methodologies , 2009, PloS one.

[33]  P. Beckert,et al.  PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data , 2015, Journal of Clinical Microbiology.

[34]  T. Kirikae,et al.  CASTB (the comprehensive analysis server for the Mycobacterium tuberculosis complex): A publicly accessible web server for epidemiological analyses, drug-resistance prediction and phylogenetic comparison of clinical isolates. , 2015, Tuberculosis.

[35]  L. Soto-Ramírez,et al.  [Treatment of tuberculosis]. , 1997, Gaceta medica de Mexico.

[36]  G. Kahlmeter,et al.  The 2014 Garrod Lecture: EUCAST - are we heading towards international agreement? , 2015, The Journal of antimicrobial chemotherapy.

[37]  David Alland,et al.  Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes , 2013, Nature Genetics.

[38]  F. Dafae,et al.  High genetic diversity among Mycobacterium tuberculosis complex strains from Sierra Leone , 2008, BMC Microbiology.

[39]  Phelim Bradley,et al.  Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis , 2015, Nature Communications.

[40]  P. de Rijk,et al.  Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.